Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
June 02 2023 - 8:50AM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that it is now actively participating on the Webull Corporate
Communications Service (CCS) Platform. The Silo Pharma portal on
Webull offers an additional channel for direct investor
communication and audience engagement, including Q&A.
“We are excited to share SILO’s new profile on Webull's
Corporate Communications Service Platform and invite investors to
take advantage of this convenient and engaging digital
communications channel,” said Eric Weisblum, Chief Executive
Officer of Silo Pharma. “The Webull CCS platform is an additional
investor relations tool that magnifies our Company’s accessibility
and transparency for active retail investors and enables us to
share unique content and communicate with them in real time.”
Stay up to date on Silo Pharma’s investor dialogue and most
recent developments by downloading the Webull app to your
smartphone or tablet device. Visit the SILO homepage on the Webull
app for our Corporate Communication Service page entrance banner.
Start following the SILO page to never miss a post.
For more information about Webull and to create a Webull
account, please visit www.webullapp.com.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
About Webull Financial
Brokerage services offered through Webull Financial LLC (“Webull
Financial”), an SEC-registered broker-dealer and member of the
Financial Industry Regulatory Authority (FINRA) and the Securities
Investor Protection Corporation (SIPC). Investment advisory
services are offered by Webull Advisors LLC (“Webull Advisors”), a
Securities and Exchange Commission (SEC) registered investment
adviser. Webull Financial and Webull Advisors are affiliates.
All investing is subject to risk, including the possible loss of
the money you invest. Neither entity guarantees profits or
protection from losses.
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Apr 2024 to May 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From May 2023 to May 2024